ClinicalTrials.gg
CompletedNCT05886244SolirisUpdated Jun 1, 2026Results posted

Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

A Phase 3 interventional study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
14th of 18
25 · median 37
Started
2023
the only one that year
Phase 3
14 of 18
none open now
Registered
16th of 18
by date
Lead sponsor
8 of 18
Alexion Pharmaceuticals, Inc.

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 14th largest by enrollment, is the only one that started in 2023, is one of 14 in phase 3, and was the 16th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

This is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in adult participants with paraxysmal noturnal hemoglobinuria (PNH) in China.

Read the detailed description

This is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in adult participants with PNH in China who previously have not been treated with complement inhibitors. Approximately 25 eligible participants in China will be enrolled.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • paroxysmal nocturnal hemoglobinuria
  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult C5 inhibitor naïve PNH patients (age>=18), which is confirmed by flow cytometry evaluation
  • Must be vaccinated against N meningitidis

Exclusion criteria

Exclusion Criteria:

  • Meningitidis infection or unresolved meningococcal disease
  • Significant bone marrow failure
  • Other significant systemic diseases that might have impact on efficacy and safety assessment
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Eculizumab will be administered by IV infusion.

    Drug: Eculizumab

Interventions

  • Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in LDH at Week 12

    Blood samples were collected for measurement of serum LDH at specified timepoints. Statistical analysis was performed using a mixed model for repeated measures (MMRM), including the percentage change from baseline of LDH at the scheduled visits from Week 1 to Week 12 as the dependent variable, with the fixed categorical effect of visit, fixed continuous effect of LDH baseline value as covariates, and participant as random effect. Assessed at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 weeks, Week 12 reported. A decrease indicated a reduction in disease activity.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that did not necessarily have to have a causal relationship with the study intervention. A TEAE was any AE that started during or after the first infusion of the study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline through Week 64

  2. Serum Concentration of Eculizumab

    Blood samples were collected for measurement of serum concentrations of eculizumab at specified timepoints. No study intervention administered on Day 449. Results reported as micrograms/milliliter (ug/mL).

    Time frame: Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449

  3. Change From Baseline in Serum Free Complement 5 (C5) Concentration

    Blood samples were collected for measurement of serum concentration of free C5 at specified timepoints. No study intervention administered on Day 449. A decrease indicated a reduction in disease activity.

    Time frame: Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449

  4. Change From Baseline in Serum Total C5 Concentration

    Blood samples were collected for measurement of serum concentration of total C5 at specified timepoints. No study intervention administered on Day 449. A decrease indicated a reduction in disease activity.

    Time frame: Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449

  5. Number of Participants With Treatment-emergent Antidrug Antibodies (ADAs) to Eculizumab

    Blood samples were collected for measurement of treatment-emergent ADAs to eculizumab at specified timepoints.

    Time frame: Baseline through Week 64

  6. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12

    The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. The FACIT-Fatigue scale is a collection of quality of life (QoL) questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores were calculated as the sum from all 13 items and ranged from 0 to 52, with higher scores indicating an increased QoL. Analysis was performed using a MMRM, including FACIT-Fatigue score change from baseline values at the scheduled visits from Week 1 to Week 12 as the dependent variable, with the fixed categorical effect of study visit, fixed continuous effect of baseline value of FACIT-Fatigue, and participant as random effect. Assessed at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 weeks, Week 12 reported.

    Time frame: Baseline, Week 12

  7. Percentage of Participants With Breakthrough Hemolysis

    Breakthrough hemolysis was defined as at least 1 new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \<10 grams/deciliter\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times (\*) upper limit of normal (ULN), after prior LDH reduction to \<1.5\* ULN on therapy.

    Time frame: Baseline through Week 12

  8. Percentage of Participants Achieving LDH Normalization

    Blood samples were collected for measurement of LDH at specified timepoints. LDH normalization was defined as LDH ≤ULN.

    Time frame: Baseline through Week 12

  9. Percentage of Participants Achieving Transfusion Avoidance

    Transfusion avoidance was defined as remaining transfusion free (that is, had not received any transfusion) and did not require transfusion as per protocol.

    Time frame: Baseline through Week 12

  10. Percentage of Participants With LDH ≤1.5* ULN at Week 12

    Blood samples were collected for measurement of LDH at specified timepoints.

    Time frame: Baseline through Week 12

07

Results

Posted Jun 1, 2026

Participant flow

Primary Treatment Period (12 Weeks)
Participant flow — Primary Treatment Period (12 Weeks)
MilestoneEculizumab
Started25
Received at least 1 dose of study drug25
Completed25
Not completed0
Long-Term Extension Period (52 Weeks)
Participant flow — Long-Term Extension Period (52 Weeks)
MilestoneEculizumab
Started25
Received at least 1 dose of study drug25
Completed20
Not completed5
Withdrew: Adverse event1
Withdrew: Other than specified1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryPercentage Change From Baseline in LDH at Week 12

Blood samples were collected for measurement of serum LDH at specified timepoints. Statistical analysis was performed using a mixed model for repeated measures (MMRM), including the percentage change from baseline of LDH at the scheduled visits from Week 1 to Week 12 as the dependent variable, with the fixed categorical effect of visit, fixed continuous effect of LDH baseline value as covariates, and participant as random effect. Assessed at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 weeks, Week 12 reported. A decrease indicated a reduction in disease activity.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in LDH at Week 12
percentage changeEculizumab
Percentage Change From Baseline in LDH at Week 12-76.5 (-87.8 to -65.2)
Statistical analysis
  • Eculizumab · MMRM · p = <0.001
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that did not necessarily have to have a causal relationship with the study intervention. A TEAE was any AE that started during or after the first infusion of the study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline through Week 64
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsEculizumab
Number of Participants With Treatment-emergent Adverse Events (TEAEs)23
SecondarySerum Concentration of Eculizumab

Blood samples were collected for measurement of serum concentrations of eculizumab at specified timepoints. No study intervention administered on Day 449. Results reported as micrograms/milliliter (ug/mL).

Time frame:
Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449
Reported as:
Geometric mean · ug/mL
Serum Concentration of Eculizumab
ug/mLEculizumab
Day 1248.81 ± 22.6
Day 29491.96 ± 31.3
Day 85507.62 ± 33.8
Day 169479.04 ± 33.3
Day 253531.03 ± 31.1
Day 337530.18 ± 41.3
Day 421594.32 ± 35.2
Day 449231.97 ± 48.6
SecondaryChange From Baseline in Serum Free Complement 5 (C5) Concentration

Blood samples were collected for measurement of serum concentration of free C5 at specified timepoints. No study intervention administered on Day 449. A decrease indicated a reduction in disease activity.

Time frame:
Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449
Reported as:
Mean · ug/mL
Change From Baseline in Serum Free Complement 5 (C5) Concentration
ug/mLEculizumab
Day 1-80.6911 ± 21.2241
Day 29-80.6911 ± 21.2241
Day 85-80.6911 ± 21.2241
Day 169-80.6911 ± 21.2241
Day 253-80.6911 ± 21.2241
Day 337-81.5460 ± 21.1775
Day 421-82.2563 ± 21.3936
Day 449-82.4700 ± 21.8728
SecondaryChange From Baseline in Serum Total C5 Concentration

Blood samples were collected for measurement of serum concentration of total C5 at specified timepoints. No study intervention administered on Day 449. A decrease indicated a reduction in disease activity.

Time frame:
Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449
Reported as:
Mean · ug/mL
Change From Baseline in Serum Total C5 Concentration
ug/mLEculizumab
Day 1-13.3422 ± 6.3902
Day 2949.5372 ± 15.2890
Day 8552.8607 ± 17.8070
Day 16950.9998 ± 17.9024
Day 25361.3600 ± 24.0315
Day 33760.9581 ± 24.3898
Day 42162.8651 ± 19.0970
Day 44964.4332 ± 22.4364
SecondaryNumber of Participants With Treatment-emergent Antidrug Antibodies (ADAs) to Eculizumab

Blood samples were collected for measurement of treatment-emergent ADAs to eculizumab at specified timepoints.

Time frame:
Baseline through Week 64
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Antidrug Antibodies (ADAs) to Eculizumab
ParticipantsEculizumab
Number of Participants With Treatment-emergent Antidrug Antibodies (ADAs) to Eculizumab0
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12

The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. The FACIT-Fatigue scale is a collection of quality of life (QoL) questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores were calculated as the sum from all 13 items and ranged from 0 to 52, with higher scores indicating an increased QoL. Analysis was performed using a MMRM, including FACIT-Fatigue score change from baseline values at the scheduled visits from Week 1 to Week 12 as the dependent variable, with the fixed categorical effect of study visit, fixed continuous effect of baseline value of FACIT-Fatigue, and participant as random effect. Assessed at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 weeks, Week 12 reported.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
score on a scaleEculizumab
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 125.6 (2.3 to 8.9)
SecondaryPercentage of Participants With Breakthrough Hemolysis

Breakthrough hemolysis was defined as at least 1 new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \<10 grams/deciliter\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times (\*) upper limit of normal (ULN), after prior LDH reduction to \<1.5\* ULN on therapy.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Breakthrough Hemolysis
percentage of participantsEculizumab
Percentage of Participants With Breakthrough Hemolysis4.0 (0.1 to 20.4)
SecondaryPercentage of Participants Achieving LDH Normalization

Blood samples were collected for measurement of LDH at specified timepoints. LDH normalization was defined as LDH ≤ULN.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving LDH Normalization
percentage of participantsEculizumab
Percentage of Participants Achieving LDH Normalization36.0 (18.0 to 57.5)
SecondaryPercentage of Participants Achieving Transfusion Avoidance

Transfusion avoidance was defined as remaining transfusion free (that is, had not received any transfusion) and did not require transfusion as per protocol.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Transfusion Avoidance
percentage of participantsEculizumab
Percentage of Participants Achieving Transfusion Avoidance96.0 (79.6 to 99.9)
SecondaryPercentage of Participants With LDH ≤1.5* ULN at Week 12

Blood samples were collected for measurement of LDH at specified timepoints.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With LDH ≤1.5* ULN at Week 12
percentage of participantsEculizumab
Percentage of Participants With LDH ≤1.5* ULN at Week 1280.0 (59.3 to 93.2)

Adverse events

Collected over Baseline through Week 64. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab1/25 (4%)9/25 (36%)21/25 (84%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventEculizumab
PneumoniaInfections and infestations3/25
Complicated appendicitisInfections and infestations1/25
EndocarditisInfections and infestations1/25
Febrile infectionInfections and infestations1/25
Hepatitis AInfections and infestations1/25
InfluenzaInfections and infestations1/25
Urinary tract infectionInfections and infestations1/25
ThrombocytopeniaBlood and lymphatic system disorders1/25
Cerebral infarctionNervous system disorders1/25
Myocardial infarctionCardiac disorders1/25
Most frequent other events
Showing 10 of 11
Most frequent other events
EventEculizumab
Upper respiratory tract infectionInfections and infestations7/25
HeadacheNervous system disorders5/25
PyrexiaGeneral disorders4/25
COVID-19Infections and infestations3/25
HyperuricaemiaMetabolism and nutrition disorders3/25
HypokalaemiaMetabolism and nutrition disorders3/25
Neutrophil count decreasedInvestigations3/25
H1N1 influenzaInfections and infestations2/25
NasopharyngitisInfections and infestations2/25
Hepatic function abnormalHepatobiliary disorders2/25

Baseline characteristics

Full Analysis Set: all participants who received at least 1 dose of study intervention and had at least 1 efficacy assessment post first dose.

Age, Continuous
Age, Continuous(years)Eculizumab
Mean40.5 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Eculizumab
Female10
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eculizumab
Hispanic or Latino0
Not Hispanic or Latino25
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eculizumab
American Indian or Alaska Native0
Asian25
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Baseline Lactate Dehydrogenase (LDH)
Baseline Lactate Dehydrogenase (LDH)(U/L)Eculizumab
Mean1657.50 ± 575.93
08

Study locations

7 sites
  • Research Site
    Beijing, CN-100730, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Nantong, 226001, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Tianjin, 300020, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Wuhan, 430022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Apr 2025, 21 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 21 months is close to that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 2, 2023
StartActual
Jul 5, 2023
Primary completionActual
Apr 14, 2025
CompletionActual
Apr 14, 2025
Results first posted
Jun 1, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05886244
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Jul 5, 2023
Primary completion
Apr 14, 2025
Completion
Apr 14, 2025
Results posted
Jun 1, 2026
Last update
Jun 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion